6-Chloro Phenoxychroman Carboxylic Acid Derivative as DP2 Antagonist
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases such as asthma and atopic dermatitis are inadequate in targeting the DP2 receptor, which plays a critical role in allergic inflammation, as existing therapies do not effectively modulate this receptor to alleviate symptoms.
Innovation Solution
Development of a novel compound, 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid, or its pharmaceutically acceptable salts, which acts as a DP2 antagonist, providing a specific mechanism to inhibit the receptor's activity and reduce allergic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for allergic diseases, then general anti-inflammatory effects are achieved, but specific modulation of the DP2 receptor is insufficient
Solution Approach 1:
The patent modifies molecular parameters by introducing specific substituents at defined positions on the chroman core structure. The 6-chloro substitution and 7-phenoxy group with 4-position amide linkage create a molecule with optimized binding characteristics for the DP2 receptor, transforming a general anti-inflammatory approach into a targeted therapy
Solution Approach 2:
The invention applies local quality by placing specific functional groups at precise locations on the molecule. The 4-position amide-linked group on the phenoxy moiety and the 6-chloro substitution on the chroman ring provide localized interactions with specific amino acid residues in the DP2 receptor binding pocket, enabling selective antagonism
2Measurement precision
If DP2 receptor antagonists are developed to specifically target allergic inflammation, then treatment precision is improved, but compound complexity increases
Solution Approach 1:
The molecule is segmented into distinct functional modules: a chroman core providing structural stability, a 6-chloro substituent for specific binding interaction, a 7-phenoxy group for aromatic stacking, and a 4-position amide-linked group for hydrogen bonding. This segmentation allows each part to contribute specifically to DP2 receptor binding while maintaining overall molecular manageability
Solution Approach 2:
The compound combines multiple chemical moieties (chroman ring, phenoxy group, amide linkage, aromatic substituents) into a composite molecular structure. Each component brings specific properties that collectively enable high-affinity, selective binding to the DP2 receptor while maintaining pharmacological stability
Data Source
AI summary
A compound which is 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)-phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. Said compound is either a racemic mixture or a single enantiomer, preferably Enantiomer 2 of 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, in particular its sodium salt. Said compound for use in treating an immunologic disorder in a mammal.